Pancreatic Cancer Research

ResearcherCedars-Sinai Medical CenterActive in the last 2 years

Natalie Moshayedi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2458-1164; OpenAlex author ID A5031066658. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2022: 5 papers · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 8

  1. Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreat… Co-author DOI 10.1200/jco-25-02199↗
  2. Fecal Microbiome Composition and Plasma Metabolomics in Pancreatic Cancer Cachexia Treated with Nutritional Support Co-author DOI 10.20944/preprints202401.0727.v1↗
  3. Plasma Metabolomics Predicts Chemotherapy Response in Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers15113020↗
  4. Hyaluronan heterogeneity in pancreatic ductal adenocarcinoma: Primary tumors compared to sites of metastasis. Co-author DOI 10.1016/j.pan.2021.09.015↗
  5. Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-022-19401-3↗
  6. Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-022-23619-6↗
  7. Gut microbiome and pancreatic cancer cachexia: An evolving relationship. Co-author DOI 10.4251/wjgo.v14.i7.1218↗
  8. Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma. Last author DOI 10.6004/jnccn.2022.7039↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrew Eugene Hendifar · 8 shared papers, 2022–2026 · strength 1.28
  2. Arsen Osipov · 8 shared papers, 2022–2026 · strength 1.28
  3. Jun Gong · 7 shared papers, 2022–2024 · strength 1.09
  4. Veronica Placencio-Hickok · 4 shared papers, 2022–2024 · strength 0.67
  5. Neil A. Bhowmick · 3 shared papers, 2022–2024 · strength 0.51
  6. Hayato Muranaka · 3 shared papers, 2022–2024 · strength 0.51
  7. Simon K. Lo · 3 shared papers, 2022 · strength 0.41
  8. Brent K. Larson · 2 shared papers, 2022–2026 · strength 0.33
  9. Stephen Jacob Pandol · 2 shared papers, 2022–2023 · strength 0.31
  10. Srinivas Gaddam · 2 shared papers, 2022 · strength 0.27
  11. Gillian K. Gresham · 2 shared papers, 2022 · strength 0.27
  12. Davendra P. S. Sohal · 1 shared paper, 2026 · strength 0.19
  13. Vivek U. Nimgaonkar · 1 shared paper, 2026 · strength 0.19
  14. Barbara T. Grünwald · 1 shared paper, 2026 · strength 0.19
  15. Haochen Zhang · 1 shared paper, 2026 · strength 0.19
  16. Robert C. Grant · 1 shared paper, 2026 · strength 0.19
  17. Kawther Abdilleh · 1 shared paper, 2026 · strength 0.19
  18. Eric Andrew Collisson · 1 shared paper, 2026 · strength 0.19
  19. Grainne Mary O'Kane · 1 shared paper, 2026 · strength 0.19
  20. Rosalie C. Sears · 1 shared paper, 2026 · strength 0.19
  21. Marcus Smith Noel · 1 shared paper, 2026 · strength 0.19
  22. Jennifer Jane Knox · 1 shared paper, 2026 · strength 0.19
  23. Christos K Fountzilas · 1 shared paper, 2026 · strength 0.19
  24. Sudheer Doss Doss · 1 shared paper, 2026 · strength 0.19
  25. Aatur Dilip Singhi · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.